Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer
Abstract
:Simple Summary
Abstract
1. Introduction
2. Materials and Methods
2.1. Patient Information and the Expression of TMED1
2.2. Survival Analysis
2.3. Protein–Protein Interaction (PPI) Network and Reactome Pathway Analysis
2.4. Immune Infiltration Analysis
2.5. Gene Set Variation Analysis (GSVA) and Drug Sensitivity Analysis
2.6. Cell Culture and RNA Interference
2.7. Real-Time Quantitative PCR
2.8. Cell Proliferation Assay
2.8.1. Crystal Violet Assay
2.8.2. CCK-8 Assay
2.9. Annexin V Apoptosis Assay
2.10. Cell Cycle Analysis
2.11. Statistical Analysis
3. Results
3.1. TMED1 Was Highly Expressed in CRC
3.2. TMED1 Predicted a Poor Prognosis in CRC
3.3. Knockdown of TMED1 Decreased Proliferation and Induced Apoptosis in CRC Cells
3.4. The Correlation between TMED1 and Immune Infiltration in CRC
3.5. TMED1 Increased the Drug Resistance of Cancer Cells
4. Discussion
5. Conclusions
Supplementary Materials
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Sung, H.; Ferlay, J.; Siegel, R.L.; Laversanne, M.; Soerjomataram, I.; Jemal, A.; Bray, F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021, 71, 209–249. [Google Scholar] [CrossRef] [PubMed]
- Morgan, E.; Arnold, M.; Gini, A.; Lorenzoni, V.; Cabasag, C.J.; Laversanne, M.; Vignat, J.; Ferlay, J.; Murphy, N.; Bray, F. Global burden of colorectal cancer in 2020 and 2040: Incidence and mortality estimates from GLOBOCAN. Gut 2023, 72, 338–344. [Google Scholar] [CrossRef] [PubMed]
- Dekker, E.; Tanis, P.J.; Vleugels, J.L.A.; Kasi, P.M.; Wallace, M.B. Colorectal cancer. Lancet 2019, 394, 1467–1480. [Google Scholar] [CrossRef] [PubMed]
- Bai, X.; Wei, H.; Liu, W.; Coker, O.O.; Gou, H.; Liu, C.; Zhao, L.; Li, C.; Zhou, Y.; Wang, G.; et al. Cigarette smoke promotes colorectal cancer through modulation of gut microbiota and related metabolites. Gut 2022, 71, 2439–2450. [Google Scholar] [CrossRef] [PubMed]
- Bardou, M.; Barkun, A.N.; Martel, M. Obesity and colorectal cancer. Gut 2013, 62, 933–947. [Google Scholar] [CrossRef] [PubMed]
- Biller, L.H.; Schrag, D. Diagnosis and Treatment of Metastatic Colorectal Cancer: A Review. JAMA 2021, 325, 669–685. [Google Scholar] [CrossRef]
- Li, N.; Lu, B.; Luo, C.; Cai, J.; Lu, M.; Zhang, Y.; Chen, H.; Dai, M. Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. Cancer Lett. 2021, 522, 255–268. [Google Scholar] [CrossRef]
- Punt, C.J.; Koopman, M.; Vermeulen, L. From tumour heterogeneity to advances in precision treatment of colorectal cancer. Nat. Rev. Clin. Oncol. 2017, 14, 235–246. [Google Scholar] [CrossRef]
- Li, C.; Sun, Y.D.; Yu, G.Y.; Cui, J.R.; Lou, Z.; Zhang, H.; Huang, Y.; Bai, C.G.; Deng, L.L.; Liu, P.; et al. Integrated Omics of Metastatic Colorectal Cancer. Cancer Cell 2020, 38, 734–774.e739. [Google Scholar] [CrossRef]
- Van Der Jeught, K.; Xu, H.C.; Li, Y.J.; Lu, X.B.; Ji, G. Drug resistance and new therapies in colorectal cancer. World J. Gastroenterol. 2018, 24, 3834–3848. [Google Scholar] [CrossRef]
- Mota, D.; Cardoso, I.A.; Mori, R.M.; Batista, M.R.B.; Basso, L.G.M.; Nonato, M.C.; Costa-Filho, A.J.; Mendes, L.F.S. Structural and thermodynamic analyses of human TMED1 (p24gamma1) Golgi dynamics. Biochimie 2022, 192, 72–82. [Google Scholar] [CrossRef]
- Pastor-Cantizano, N.; Montesinos, J.C.; Bernat-Silvestre, C.; Marcote, M.J.; Aniento, F. p24 family proteins: Key players in the regulation of trafficking along the secretory pathway. Protoplasma 2016, 253, 967–985. [Google Scholar] [CrossRef]
- Dvela-Levitt, M.; Kost-Alimova, M.; Emani, M.; Kohnert, E.; Thompson, R.; Sidhom, E.H.; Rivadeneira, A.; Sahakian, N.; Roignot, J.; Papagregoriou, G.; et al. Small Molecule Targets TMED9 and Promotes Lysosomal Degradation to Reverse Proteinopathy. Cell 2019, 178, 521–535.e23. [Google Scholar] [CrossRef]
- Aber, R.; Chan, W.; Mugisha, S.; Jerome-Majewska, L.A. Transmembrane emp24 domain proteins in development and disease. Genet. Res. 2019, 101, e14. [Google Scholar] [CrossRef] [PubMed]
- Zhou, L.; Li, H.; Yao, H.; Dai, X.; Gao, P.; Cheng, H. TMED family genes and their roles in human diseases. Int. J. Med. Sci. 2023, 20, 1732–1743. [Google Scholar] [CrossRef] [PubMed]
- Yang, Y.; Liu, S.; Xie, C.; Li, Q.; Gao, T.; Liu, M.; Xi, M.; Zhao, L. Trafficking protein TMED3 promotes esophageal squamous cell carcinoma. Biomed. J. 2023, 46, 100528. [Google Scholar] [CrossRef] [PubMed]
- Cheng, X.; Deng, X.; Zeng, H.; Zhou, T.; Li, D.; Zheng, W.V. Silencing of TMED5 inhibits proliferation, migration and invasion, and enhances apoptosis of hepatocellular carcinoma cells. Adv. Clin. Exp. Med. 2023, 32, 677–688. [Google Scholar] [CrossRef] [PubMed]
- Gao, W.; Zhang, Z.W.; Wang, H.Y.; Li, X.D.; Peng, W.T.; Guan, H.Y.; Liao, Y.X.; Liu, A. TMED2/9/10 Serve as Biomarkers for Poor Prognosis in Head and Neck Squamous Carcinoma. Front. Genet. 2022, 13, 895281. [Google Scholar] [CrossRef]
- Lin, X.; Liu, J.; Hu, S.F.; Hu, X. Increased expression of TMED2 is an unfavorable prognostic factor in patients with breast cancer. Cancer Manag. Res. 2019, 11, 2203–2214. [Google Scholar] [CrossRef] [PubMed]
- Xie, A.; Xu, X.; Kuang, P.; Zhang, L.; Yu, F. TMED3 promotes the progression and development of lung squamous cell carcinoma by regulating EZR. Cell Death Dis. 2021, 12, 804. [Google Scholar] [CrossRef]
- Guo, X.; Yin, X.; Xu, Y.; Li, L.; Yuan, M.; Zhao, H.; Jiang, Y.; Shi, X.; Bi, H.; Liu, Y.; et al. TMED3 promotes the development of malignant melanoma by targeting CDCA8 and regulating PI3K/Akt pathway. Cell Biosci. 2023, 13, 65. [Google Scholar] [CrossRef]
- Yang, Z.; Sun, Q.; Guo, J.; Wang, S.; Song, G.; Liu, W.; Liu, M.; Tang, H. GRSF1-mediatedMIR-G-1promotes malignant behavior and nuclear autophagy by directly upregulatingTMED5andLMNB1in cervical cancer cells. Autophagy 2018, 15, 668–685. [Google Scholar] [CrossRef]
- Mishra, S.; Bernal, C.; Silvano, M.; Anand, S.; Ruiz, I.a.A. The protein secretion modulator TMED9 drives CNIH4/TGFalpha/GLI signaling opposing TMED3-WNT-TCF to promote colon cancer metastases. Oncogene 2019, 38, 5817–5837. [Google Scholar] [CrossRef]
- Yang, Y.C.; Chien, M.H.; Lai, T.C.; Tung, M.C.; Jan, Y.H.; Chang, W.M.; Jung, S.M.; Chen, M.H.; Yeh, C.N.; Hsiao, M. Proteomics-based identification of TMED9 is linked to vascular invasion and poor prognoses in patients with hepatocellular carcinoma. J. Biomed. Sci. 2021, 28, 29. [Google Scholar] [CrossRef]
- Jiang, Y.; Sun, A.; Zhao, Y.; Ying, W.; Sun, H.; Yang, X.; Xing, B.; Sun, W.; Ren, L.; Hu, B.; et al. Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma. Nature 2019, 567, 257–261. [Google Scholar] [CrossRef]
- Gao, Q.; Zhu, H.; Dong, L.; Shi, W.; Chen, R.; Song, Z.; Huang, C.; Li, J.; Dong, X.; Zhou, Y.; et al. Integrated Proteogenomic Characterization of HBV-Related Hepatocellular Carcinoma. Cell 2019, 179, 561–577.e22. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.; Zhao, Y.; Kong, P.; Liu, Y.; Huang, J.; Xu, E.; Wei, W.; Li, G.; Cheng, X.; Xue, L.; et al. Integrated multi-omics profiling yields a clinically relevant molecular classification for esophageal squamous cell carcinoma. Cancer Cell 2023, 41, 181–195.e9. [Google Scholar] [CrossRef] [PubMed]
- Dong, L.; Lu, D.; Chen, R.; Lin, Y.; Zhu, H.; Zhang, Z.; Cai, S.; Cui, P.; Song, G.; Rao, D.; et al. Proteogenomic characterization identifies clinically relevant subgroups of intrahepatic cholangiocarcinoma. Cancer Cell 2022, 40, 70–87.e15. [Google Scholar] [CrossRef] [PubMed]
- Deng, M.; Ran, P.; Chen, L.; Wang, Y.; Yu, Z.; Cai, K.; Feng, J.; Qin, Z.; Yin, Y.; Tan, S.; et al. Proteogenomic characterization of cholangiocarcinoma. Hepatology 2023, 77, 411–429. [Google Scholar] [CrossRef] [PubMed]
- Xu, J.-Y.; Zhang, C.; Wang, X.; Zhai, L.; Ma, Y.; Mao, Y.; Qian, K.; Sun, C.; Liu, Z.; Jiang, S.; et al. Integrative Proteomic Characterization of Human Lung Adenocarcinoma. Cell 2020, 182, 245–261.e17. [Google Scholar] [CrossRef] [PubMed]
- Consortium, G.T. The Genotype-Tissue Expression (GTEx) project. Nat. Genet. 2013, 45, 580–585. [Google Scholar] [CrossRef]
- Tang, Z.; Li, C.; Kang, B.; Gao, G.; Li, C.; Zhang, Z. GEPIA: A web server for cancer and normal gene expression profiling and interactive analyses. Nucleic Acids Res. 2017, 45, W98–W102. [Google Scholar] [CrossRef] [PubMed]
- Chandrashekar, D.S.; Karthikeyan, S.K.; Korla, P.K.; Patel, H.; Shovon, A.R.; Athar, M.; Netto, G.J.; Qin, Z.S.; Kumar, S.; Manne, U.; et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia 2022, 25, 18–27. [Google Scholar] [CrossRef]
- Navani, S. Manual evaluation of tissue microarrays in a high-throughput research project: The contribution of Indian surgical pathology to the Human Protein Atlas (HPA) project. Proteomics 2016, 16, 1266–1270. [Google Scholar] [CrossRef] [PubMed]
- Goldman, M.J.; Craft, B.; Hastie, M.; Repecka, K.; Mcdade, F.; Kamath, A.; Banerjee, A.; Luo, Y.; Rogers, D.; Brooks, A.N.; et al. Visualizing and interpreting cancer genomics data via the Xena platform. Nat. Biotechnol. 2020, 38, 675–678. [Google Scholar] [CrossRef]
- Brunson, J.C. ggalluvial: Layered Grammar for Alluvial Plots. J. Open Source Softw. 2020, 5, 2017. [Google Scholar] [CrossRef] [PubMed]
- Lanczky, A.; Gyorffy, B. Web-Based Survival Analysis Tool Tailored for Medical Research (KMplot): Development and Implementation. J. Med. Internet Res. 2021, 23, e27633. [Google Scholar] [CrossRef]
- Szklarczyk, D.; Gable, A.L.; Lyon, D.; Junge, A.; Wyder, S.; Huerta-Cepas, J.; Simonovic, M.; Doncheva, N.T.; Morris, J.H.; Bork, P.; et al. STRING v11: Protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019, 47, D607–D613. [Google Scholar] [CrossRef]
- Jassal, B.; Matthews, L.; Viteri, G.; Gong, C.; Lorente, P.; Fabregat, A.; Sidiropoulos, K.; Cook, J.; Gillespie, M.; Haw, R.; et al. The reactome pathway knowledgebase. Nucleic Acids Res. 2020, 48, D498–D503. [Google Scholar] [CrossRef]
- Li, T.; Fu, J.; Zeng, Z.; Cohen, D.; Li, J.; Chen, Q.; Li, B.; Liu, X.S. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Res. 2020, 48, W509–W514. [Google Scholar] [CrossRef]
- Li, T.; Fan, J.; Wang, B.; Traugh, N.; Chen, Q.; Liu, J.S.; Li, B.; Liu, X.S. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Res. 2017, 77, e108–e110. [Google Scholar] [CrossRef]
- Newman, A.M.; Liu, C.L.; Green, M.R.; Gentles, A.J.; Feng, W.; Xu, Y.; Hoang, C.D.; Diehn, M.; Alizadeh, A.A. Robust enumeration of cell subsets from tissue expression profiles. Nat. Methods 2015, 12, 453–457. [Google Scholar] [CrossRef] [PubMed]
- Finotello, F.; Mayer, C.; Plattner, C.; Laschober, G.; Rieder, D.; Hackl, H.; Krogsdam, A.; Loncova, Z.; Posch, W.; Wilflingseder, D.; et al. Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data. Genome Med. 2019, 11, 34. [Google Scholar] [CrossRef] [PubMed]
- Aran, D.; Hu, Z.; Butte, A.J. xCell: Digitally portraying the tissue cellular heterogeneity landscape. Genome Biol. 2017, 18, 220. [Google Scholar] [CrossRef] [PubMed]
- Becht, E.; Giraldo, N.A.; Lacroix, L.; Buttard, B.; Elarouci, N.; Petitprez, F.; Selves, J.; Laurent-Puig, P.; Sautes-Fridman, C.; Fridman, W.H.; et al. Estimating the population abundance of tissue-infiltrating immune and stromal cell populations using gene expression. Genome Biol. 2016, 17, 218. [Google Scholar] [CrossRef]
- Sturm, G.; Finotello, F.; Petitprez, F.; Zhang, J.D.; Baumbach, J.; Fridman, W.H.; List, M.; Aneichyk, T. Comprehensive evaluation of transcriptome-based cell-type quantification methods for immuno-oncology. Bioinformatics 2019, 35, i436–i445. [Google Scholar] [CrossRef]
- Pao, W.; Ooi, C.H.; Birzele, F.; Ruefli-Brasse, A.; Cannarile, M.A.; Reis, B.; Scharf, S.H.; Schubert, D.A.; Hatje, K.; Pelletier, N.; et al. Tissue-Specific Immunoregulation: A Call for Better Understanding of the “Immunostat” in the Context of Cancer. Cancer Discov. 2018, 8, 395–402. [Google Scholar] [CrossRef]
- Angelova, M.; Charoentong, P.; Hackl, H.; Fischer, M.L.; Snajder, R.; Krogsdam, A.M.; Waldner, M.J.; Bindea, G.; Mlecnik, B.; Galon, J.; et al. Characterization of the immunophenotypes and antigenomes of colorectal cancers reveals distinct tumor escape mechanisms and novel targets for immunotherapy. Genome Biol. 2015, 16, 64. [Google Scholar] [CrossRef] [PubMed]
- Liu, C.J.; Hu, F.F.; Xie, G.Y.; Miao, Y.R.; Li, X.W.; Zeng, Y.; Guo, A.Y. GSCA: An integrated platform for gene set cancer analysis at genomic, pharmacogenomic and immunogenomic levels. Brief. Bioinform. 2023, 24, bbac558. [Google Scholar] [CrossRef]
- Rees, M.G.; Seashore-Ludlow, B.; Cheah, J.H.; Adams, D.J.; Price, E.V.; Gill, S.; Javaid, S.; Coletti, M.E.; Jones, V.L.; Bodycombe, N.E.; et al. Correlating chemical sensitivity and basal gene expression reveals mechanism of action. Nat. Chem. Biol. 2016, 12, 109–116. [Google Scholar] [CrossRef]
- Yang, W.; Soares, J.; Greninger, P.; Edelman, E.J.; Lightfoot, H.; Forbes, S.; Bindal, N.; Beare, D.; Smith, J.A.; Thompson, I.R.; et al. Genomics of Drug Sensitivity in Cancer (GDSC): A resource for therapeutic biomarker discovery in cancer cells. Nucleic Acids Res. 2013, 41, D955–D961. [Google Scholar] [CrossRef] [PubMed]
- Marquart, J.; Chen, E.Y.; Prasad, V. Estimation of the Percentage of US Patients With Cancer Who Benefit From Genome-Driven Oncology. JAMA Oncol. 2018, 4, 1093–1098. [Google Scholar] [CrossRef] [PubMed]
- Roberts, B.S.; Satpute-Krishnan, P. The many hats of transmembrane emp24 domain protein TMED9 in secretory pathway homeostasis. Front. Cell Dev. Biol. 2022, 10, 1096899. [Google Scholar] [CrossRef] [PubMed]
- Zhang, D.; Sun, L.; Zhang, J. TMED3 exerts a protumor function in non-small cell lung cancer by enhancing the Wnt/β-catenin pathway via regulation of AKT. Toxicol. Appl. Pharmacol. 2021, 433, 115793. [Google Scholar] [CrossRef] [PubMed]
- Huang, R.Y.J.; Huang, K.J.; Chen, K.C.; Hsiao, S.M.; Tan, T.Z.; Wu, C.J.; Hsu, C.; Chang, W.C.; Pan, C.Y.; Sheu, B.C.; et al. Immune-Hot tumor features associated with recurrence in early-stage ovarian clear cell carcinoma. Int. J. Cancer 2023, 152, 2174–2185. [Google Scholar] [CrossRef] [PubMed]
- Bindea, G.; Mlecnik, B.; Tosolini, M.; Kirilovsky, A.; Waldner, M.; Obenauf, A.C.; Angell, H.; Fredriksen, T.; Lafontaine, L.; Berger, A.; et al. Spatiotemporal dynamics of intratumoral immune cells reveal the immune landscape in human cancer. Immunity 2013, 39, 782–795. [Google Scholar] [CrossRef] [PubMed]
- Connolly, D.J.; O’neill, L.A.; Mcgettrick, A.F. The GOLD domain-containing protein TMED1 is involved in interleukin-33 signaling. J. Biol. Chem. 2013, 288, 5616–5623. [Google Scholar] [CrossRef]
- Fenech, E.J.; Lari, F.; Charles, P.D.; Fischer, R.; Laetitia-Thezenas, M.; Bagola, K.; Paton, A.W.; Paton, J.C.; Gyrd-Hansen, M.; Kessler, B.M.; et al. Interaction mapping of endoplasmic reticulum ubiquitin ligases identifies modulators of innate immune signalling. Elife 2020, 9, e57306. [Google Scholar] [CrossRef]
- Baharom, F.; Ramirez-Valdez, R.A.; Khalilnezhad, A.; Khalilnezhad, S.; Dillon, M.; Hermans, D.; Fussell, S.; Tobin, K.K.S.; Dutertre, C.-A.; Lynn, G.M.; et al. Systemic vaccination induces CD8+ T cells and remodels the tumor microenvironment. Cell 2022, 185, 4317–4332.e15. [Google Scholar] [CrossRef]
- Nishikawa, H.; Koyama, S. Mechanisms of regulatory T cell infiltration in tumors: Implications for innovative immune precision therapies. J. Immunother. Cancer 2021, 9, e002591. [Google Scholar] [CrossRef]
- Fiori, M.E.; Di Franco, S.; Villanova, L.; Bianca, P.; Stassi, G.; De Maria, R. Cancer-associated fibroblasts as abettors of tumor progression at the crossroads of EMT and therapy resistance. Mol. Cancer 2019, 18, 70. [Google Scholar] [CrossRef]
- Choi, H.; Moon, A. Crosstalk between cancer cells and endothelial cells: Implications for tumor progression and intervention. Arch. Pharm. Res. 2018, 41, 711–724. [Google Scholar] [CrossRef]
- Speiser, D.E.; Chijioke, O.; Schaeuble, K.; Münz, C. CD4(+) T cells in cancer. Nat. Cancer 2023, 4, 317–329. [Google Scholar] [CrossRef] [PubMed]
- Laumont, C.M.; Nelson, B.H. B cells in the tumor microenvironment: Multi-faceted organizers, regulators, and effectors of anti-tumor immunity. Cancer Cell 2023, 41, 466–489. [Google Scholar] [CrossRef] [PubMed]
- Bagchi, S.; Yuan, R.; Engleman, E.G. Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance. Annu. Rev. Pathol. 2021, 16, 223–249. [Google Scholar] [CrossRef]
- Vasan, N.; Baselga, J.; Hyman, D.M. A view on drug resistance in cancer. Nature 2019, 575, 299–309. [Google Scholar] [CrossRef]
- Peterson, Q.P.; Goode, D.R.; West, D.C.; Ramsey, K.N.; Lee, J.J.Y.; Hergenrother, P.J. PAC-1 Activates Procaspase-3 in Vitro through Relief of Zinc-Mediated Inhibition. J. Mol. Biol. 2009, 388, 144–158. [Google Scholar] [CrossRef] [PubMed]
- Danciu, O.C.; Holdhoff, M.; Peterson, R.A.; Fischer, J.H.; Liu, L.C.; Wang, H.; Venepalli, N.K.; Chowdhery, R.; Nicholas, M.K.; Russell, M.J.; et al. Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies. Br. J. Cancer 2022, 128, 783–792. [Google Scholar] [CrossRef]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Guo, X.; Zhou, W.; Jin, J.; Lin, J.; Zhang, W.; Zhang, L.; Luan, X. Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer. Biology 2024, 13, 83. https://doi.org/10.3390/biology13020083
Guo X, Zhou W, Jin J, Lin J, Zhang W, Zhang L, Luan X. Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer. Biology. 2024; 13(2):83. https://doi.org/10.3390/biology13020083
Chicago/Turabian StyleGuo, Xin, Wei Zhou, Jinmei Jin, Jiayi Lin, Weidong Zhang, Lijun Zhang, and Xin Luan. 2024. "Integrative Multi-Omics Analysis Identifies Transmembrane p24 Trafficking Protein 1 (TMED1) as a Potential Prognostic Marker in Colorectal Cancer" Biology 13, no. 2: 83. https://doi.org/10.3390/biology13020083